Christopher Rovaldi
Chief Operating Officer presso KEROS THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Christopher Rovaldi è SVP-Program Management & Operations alla Acceleron Pharma, Inc. Il sig. Rovaldi ha precedentemente ricoperto la posizione di Direttore-Project Management presso Idenix Pharmaceuticals LLC, Senior Research Associate di Periodontix, Inc. e Direttore-Project Management presso Cubist Pharmaceuticals LLC. Ha conseguito una laurea e un diploma di laurea presso l'Università del New Hampshire.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
KEROS THERAPEUTICS, INC.
-.--% | 13/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Christopher Rovaldi
Società | Posizione | Inizio |
---|---|---|
KEROS THERAPEUTICS, INC. | Chief Operating Officer | 01/02/2022 |
NS Pharma, Inc.
NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The private company is based in Paramus, NJ. | President | 01/05/2019 |
Precedenti posizioni note di Christopher Rovaldi
Società | Posizione | Fine |
---|---|---|
ACCELERON PHARMA INC. | Chief Operating Officer | 01/05/2018 |
IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2007 |
CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2004 |
Periodontix, Inc.
Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The private company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Corporate Officer/Principal | - |
Formazione di Christopher Rovaldi
University of New Hampshire | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
KEROS THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Periodontix, Inc.
Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The private company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Commercial Services |
NS Pharma, Inc.
NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The private company is based in Paramus, NJ. | Health Technology |
- Borsa valori
- Insiders
- Christopher Rovaldi